The product is a protein composed of 191 amino acid residues or 192 amino acid residues with a methionine at the N-terminal, and appropriate excipients or stabilizers can be added. The amount of recombinant human growth hormone should be 90.0%~110.0% of the labeled amount.
During the production process, use the in vivo biological assay method to determine the biological titer, and the titer per 1 mg of protein shall not be less than 2.5 units.
Residual host DNA and host cell proteins in recombinant human growth hormone are potentially specific impurities related to the production process, which must be strictly controlled during the production process, and their limits should comply with relevant regulations.
Recombinant human growth hormone (r-hGH) is produced by recombinant DNA technology. Its chemical structure including amino acid sequence and amino acid composition has been identified as exactly the same as that of pituitary growth hormone. Recombinant human growth hormone (r-hGH), with the molecular formula C990H1529N2630299S7, is a polypeptide chain composed of 191 amino acids. It is connected by disulfide bonds between position 53 and 165 and between 182 and 189, and the relative molecular mass is 22125.
In the medical environment, growth forms are used to help treat various health conditions. Especially in the case of children with insufficient growth hormone production, the most obvious prescription. Although it is usually not completely correct, the use of growth hormone can usually significantly increase the linear growth rate and overall height before further growth stops during puberty.
The drug can also be used to accelerate the growth of children who were born small and failed to catch up at the age of 2 years. Other uses include the treatment of short bowel syndrome, growth disorders caused by renal insufficiency, muscle atrophy associated with HIV infection, and adult growth hormone deficiency.
With age, growth hormone levels tend to decline. Many doctors believe that supplementing menopausal levels can help slow down some of the damage of aging. Given its beneficial metabolic effects on muscle mass, strength, energy, cell regeneration and fat loss, there are many proponents of this use, even though hGH may not particularly delay the aging process.
Please note that in order to prescribe hGH for adult hormone deficiency in the United States. The patient must have a history of confirmed pituitary disease or GH deficiency in children. Under federal law, it is illegal to prescribe growth myosin for any off-label use, including anti-aging and fitness purposes.
Growth hormone can be given by subcutaneous or intramuscular injection. During the clinical study, the pharmacokinetic properties of the growth hormone after the two methods were determined. When given by subcutaneous injection, growth hormone has a similar but moderate level of bioavailability (75% vs. 63%).
The drug metabolism rates after the two routes are also very similar. Growth hormones show half-lives of about 3.8 hours and 4.9 hours after subcutaneous and intramuscular injection, respectively. Baseline hormone levels are usually reached 12 to 18 hours after injection, and the time of intramuscular injection is slower.
However, considering the delayed rise of IGF-1 levels, hGH can remain elevated 24 hours after injection, and the metabolic activity of human growth hormone will exceed its actual level in the body. Although both methods of use are acceptable for drug absorption, daily subcutaneous administration is generally considered to be the preferred method of using growth hormone.
A detailed analysis of the growth stimulus sex revealed hormones with multiple effects. It is the anabolism of skeletal muscle, which shows an increase in the size and number of cells (processes called hypertrophy and hyperplasia, respectively). This hormone seems to have a growth-promoting effect on all organs of the body, excluding the eyes and brain.
Growth hormone has a diabetic effect on carbohydrate metabolism, which means that it leads to increased blood sugar levels (a process usually associated with diabetes). Over administration of growth hormone over time may induce a state of type 2 (insulin resistance) diabetes.
This hormone also supports the hydrolysis of triglycerides in adipose tissue and can reduce fat storage in the body. Consistent with this is often a reduction in serum cholesterol. The drug also reduces the levels of potassium, phosphorus and sodium, which may cause the thyroid hormone trishard thyronine (T3) to decrease.
The latter effect marks a decrease in the metabolism of thyroid support and may interfere with the effectiveness of growth hormone prolonged therapy. Growth hormone has direct and indirect effects. On the direct side, hGH protein attaches to receptors in muscle, bone, and adipose tissue, sending messages to support anabolism and lipolysis (fat reduction).
Growth hormone also directly increases glucose synthesis (gluconeogenesis) in the liver and induces insulin resistance by blocking its activity in cells. The indirect effects of growth hormone are mainly mediated by IGF-1 (insulin-like growth factor), which is produced in response to growth hormone in the liver and almost all other tissues.
IGF-1 is also anabolic to muscles and bones, increasing the activity of growth hormone. However, IGF-1 also has a strong antagonistic effect on growth hormone. This includes increased fat production (fat retention), increased glucose consumption and reduced gluconeogenesis.
The synergy and antagonism of these two hormones combine to form the characteristics of hGH. Similarly, they also determine the effects of growth hormone administration, including support for lipolysis, increased blood sugar levels and decreased insulin sensitivity. Growth hormone is considered a controversial anabolic and performance-enhancing drug in the field of bodybuilding and sports.
The main issue of contention is the exact extent of the potential benefits that this substance brings. Although studies on HIV+ electric people in the state of weight loss tend to support potential strong anabolic and anti-metabolic properties, there is a lack of studies demonstrating these same effects for healthy adults and athletes.
In the 1980s, a large number of myths revolved around the discussion of hGH in the fitness industry, which may be driven by the high cost of the drug and its name (“growth hormone”). It was once considered the most powerful anabolic substance you can buy. Today, recombinant human growth hormone is more readily available and easy to obtain.
Nowadays, most experienced people tend to think that the fat loss-promoting properties of growth hormone are the most obvious. The drug can support muscle growth, increase in strength and increase athletic performance, but its effects are generally milder than those of anabolic/androgenic steroids. However, for a very advanced athlete or bodybuilder, growth hormone can help promote the body and performance more than steroids alone.
The first human growth hormone preparation used in medicine was made from human pituitary extracts. These are now commonly known as cadaveric growth hormone preparations. Approximately 1 mg of hcn (1 day dose) can be obtained from each corpse. The first successful treatment of human GH was reported in 1958. These drugs were introduced to the market shortly after they were sold in the United States until 1985.
The U.S. Food and Drug Administration banned their use in the year associated with the development of Croyt-Felt-Jacob disease (CJD), a highly degrading and ultimately fatal disease. In many patients, brain diseases. In special cases (usually involving blood transfusions or organ implants), the disease can spread from one person to another, and may be caused by the extraction of hGH from infected households.
The incubation period of CJD is very slow, and it is diagnosed within 4 to 30 years after the user’s body-sourced growth hormone therapy. As of 2004 estimates, at least 26 patients who have received cadaveric GH medication in the United States have been diagnosed with this disease. The overall incidence of the disease is less than 1%, because it is reported that about 6.000 patients have received medication.
The FDA approved the first synthetic human growth hormone drug in 1985. The synthetically produced pure hormone has no biological pollution, eliminating the possibility of CJD transmission. The approval of the drug is called PROTROPIN, and based on the manufacturing technology Somotono developed by Genen-tech in 1979, the FDA gave an important moment for the removal of GH from corpses in the same year.
This hormone is actually a micro-variant of hGH protein, but it shows the same biological characteristics as the natural hormone. Protropin was initially very successful because it was the first synthetic GH product. However, by 1987, KabiVitrum (Sweden) had published a method for producing pure synthetic growth hormone, which had the exact amino acid sequence of endogenous growth hormone. It was also found that the unnatural structure of somatrem leads to a much higher incidence of antibody reactions in patients, which can reduce the efficacy of the drug. Growth hormone will be regarded as a more reliable drug and will dominate the global market within a few years. Today, although somatrem products are still on sale, growth hormone still accounts for the vast majority of global HGH sales.
Growth hormone is most commonly found in multi-dose vials containing white lyophilized powder and needs to be reconstituted with sterile or bacteriostatic water before use. The dosage can vary from 1 mg to 24 mg or more per bottle of small fish. Growth hormone can also be used as a stable pre-mixed solution (Nutropin AQ), which is biologically equivalent to recombinant growth hormone.
Growth hormone is a human growth hormone protein produced by recombinant DNA technology. It has 191 amino acid residues and a molecular weight of 22,125 Daltons. Its structure is the same as human growth hormone derived from the pituitary gland.
Don’t freeze. Obtain storage information in accordance with the package instructions. Cooling may be required before and after reconstruction (2° to 8°C, 35° to 46°F).
The most common adverse reactions to growth hormone therapy are joint pain, headache, flu-like symptoms, peripheral edema (water retention) and back pain. Less common adverse reactions include inflammation of the nasal mucosa (rhinitis), dizziness, upper respiratory tract infection, bronchitis, skin spurs or numbness, decreased tactile sensitivity, systemic edema, nausea, bone pain, carpal tunnel syndrome, chest pain, depression , Gynecomastia, hypothyroidism and insomnia. The abuse of growth hormone can lead to diabetes, acromegaly (significant thickening of bones, most notably the feet, forehead, hands, jaw and elbow), and enlargement of internal organs. Due to the growth-promoting effects of human growth hormone, this drug should not be used by individuals with active or recurrent cancer.
If you want to buy this product, you can log in https://www.vivalr.com/contact-us